The Medical Letter on Drugs and Therapeutics
January 13, 2020
Antiviral Drugs for Influenza
|Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.|
Antiviral Drugs for Influenza
January 13, 2020 (Issue: 1589)
- Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015; 57:17.
- Baloxavir marboxil (Xofluza) for treatment of influenza. Med Lett Drugs Ther 2018; 60:193.
- CDC. Influenza antiviral medications: summary for clinicians. Available at: www.cdc.gov/flu. Accessed December 20, 2019.
- T Uyeki et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on diagnosis, treatment, chemo-prophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68:e1.
- Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2019-2020. Pediatrics 2019; 144:e20192478.
- CDC. Information for clinicians on influenza virus testing. Available at: www.cdc.gov. Accessed December 20, 2019.
- J Dobson et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.
- IDSA. IDSA statement on neuraminidase inhibitors. Available at: http://bit.ly/34AdhEU. Accessed December 20, 2019.
- FG Hayden et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913.
- RE Malosh et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis 2018; 66:1492.
- In brief: concerns about oseltamivir (Tamiflu). Med Lett Drugs Ther 2015; 57:14.
- MK Doll et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother 2017; 72:2990.
- J Katzen et al. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2019; 69:52.
- MG Ison et al. Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 Study). Presented at ID Week, San Francisco, CA, Oct 3-7, 2018. Abstract LB16. Available at: http://bit.ly/2PCO3Bh. Accessed December 20, 2018.
- JK Louie et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539.
- SG Muthuri et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395.
- JK Louie et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198.
- JP Metlay et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.
- S Graner et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017; 356:j629.
- V Ehrenstein et al. Oseltamivir in pregnancy and birth outcomes. BMC Infect Dis 2018; 18:519.
- ACOG Committee Opinion No. 753: assessment and treatment of pregnant women with suspected or confirmed influenza. Obstet Gynecol 2018; 132:e169.
- IK Oboho et al. Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza. J Infect Dis 2016; 214:507.
- CDC. Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. Available at: www.cdc.gov. Accessed December 20, 2019.
- A Lackenby et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antiviral Res 2018; 157:38.
- AC Hurt et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148.
- C Renaud et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653.
- JW Tang et al. Transmitted and acquired oseltamivir resistance during the 2018-2019 influenza season. J Infec 2019; 79:612.
- R Roosenhoff et al. Viral kinetics and resistance development in children treated with neuraminidase inhibitors: the Influenza Resistance Information Study (IRIS). Clin Infec Dis 2019 Sep 27 (epub).
- E Takashita et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill 2016; 21:pii=30258.
- R Trebbien et al. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017; 22:pii=30445.
- E Mitha et al. Safety, resistance, and efficacy results from a phase IIIb study of conventional- and double-dose oseltamivir regimens for treatment of influenza in immunocompromised patients. Infect Dis Ther 2019; 8:613.
- E Takashita et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit 138T substitution detected from a hospitalized child without prior baloxavir treatment, Japan, January 2019. Euro Surveill 2019; 24:pii=1900170.
- E Takashita et al. Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerging Infectious Diseases 2019; 25:2108.
- M Seki et al. Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. ID Cases 2019; 18:e00650.
- S Toovey et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 2012; 29:826.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.